InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.045 0.005 (12.50%)+
Announcement
Release
11 Jun 2026 9:10AM
Price at Release
$0.040
Full Release
download
Summary
The presentation provides an update on Emyria Limited, highlighting its strategic focus on advanced therapies, specifically in psychedelic-assisted treatments for mental health conditions such as PTSD and treatment-resistant depression. Emyria is establishing a national network of clinics specialized in these therapies, capitalizing on recent regulatory changes in Australia which now allow prescribing MDMA and psilocybin by authorized psychiatrists. This regulatory shift positions Emyria with a first-mover advantage in a significant market opportunity. The presentation emphasizes Emyria's comprehensive treatment model, which includes screening, active treatment, and follow-up phases, with a significant projected total addressable market given the prevalence of conditions like major depression and PTSD in Australia.
Key Points
  • Emyria is focusing on advanced therapies and compassionate care.
  • The company is building a national network for psychedelic-assisted therapy for PTSD and depression.
  • Recent regulatory changes in Australia have allowed prescribing MDMA and psilocybin.
  • Emyria has a first-mover advantage in the psychedelic therapy market.
  • The treatment model includes screening, active treatment, and follow-up.
  • Significant market opportunity due to the prevalence of PTSD and major depression in Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.